Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Atrium Therapeutics, Inc. - Common Stock (NQ:RNA)

12.68 -0.32 (-2.46%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jun 1, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	209,591
Open	13.00
Bid (Size)	12.10 (100)
Ask (Size)	13.16 (200)
Prev. Close	13.00
Today's Range	12.35 - 13.10
52wk Range	11.95 - 73.06
Shares Outstanding	54,462,518
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Sarepta's RNA Renaissance: 35% Surge as siRNA Breakthrough Silences Skeptics

March 26, 2026

CAMBRIDGE, MA — March 26, 2026 — Shares of Sarepta Therapeutics (NASDAQ: SRPT) skyrocketed 35% in early trading today, reaching levels not seen since the company’s early days in Duchenne Muscular...

Via MarketMinute

Top movers in Friday's after hours session ↗

February 27, 2026

Via Chartmill

Performance

YTD	-82.4%	-82.4%
1 Month	-1.5%	-1.5%
3 Month	-15.0%	-15.0%
6 Month	-82.2%	-82.2%
1 Year	-61.8%	-61.8%

More News

The Era of the Titans: Q4 2025 Mega-Deal Surge and the 2026 Economic Map

February 06, 2026

Via MarketMinute

Halper Sadeh LLC Encourages TWO, RNA, CVBF, TBN Shareholders to Contact the Firm to Discuss Their Rights

January 31, 2026

From Halper Sadeh LLC

Via GlobeNewswire

The Biotech Renaissance: Scientific Breakthroughs and M&A Frenzy Spark a New Bull Market

January 22, 2026

Via MarketMinute

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

Via MarketMinute

Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal

December 29, 2025

Via MarketMinute

The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally

December 22, 2025

Via MarketMinute

This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗

December 03, 2025

Via The Motley Fool

Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗

November 28, 2025

Via The Motley Fool

Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗

November 27, 2025

Via The Motley Fool

This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗

November 27, 2025

Via The Motley Fool

Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year ↗

November 27, 2025

Via The Motley Fool

Halper Sadeh LLC Encourages WTRG, RNA, TCBX Shareholders to Contact the Firm to Discuss Their Rights

November 22, 2025

From Halper Sadeh LLC

Via GlobeNewswire

Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts ↗

November 20, 2025

Via Benzinga

Here's How Much $100 Invested In Avidity Biosciences 5 Years Ago Would Be Worth Today ↗

November 19, 2025

Via Benzinga

Looking Into Avidity Biosciences Inc's Recent Short Interest ↗

November 19, 2025

Via Benzinga

Biopharma Boom: M&A Frenzy, AI Revolution, and GLP-1 Gold Rush Drive Robust Growth in 2025

November 14, 2025

Via MarketMinute

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Essential Utilities, Inc. (NYSE – WTRG), Cadence Bank (NYSE – CADE), Avidity Biosciences, Inc. (Nasdaq – RNA), Plymouth Industrial REIT, Inc. (NYSE – PLYM)

November 06, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think) ↗

October 31, 2025

Via The Motley Fool

Unusual volume stocks in Thursday's session ↗

October 30, 2025

Via Chartmill

$1000 Invested In Avidity Biosciences 5 Years Ago Would Be Worth This Much Today ↗

October 29, 2025

Via Benzinga

RNA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Avidity Biosciences, Inc. is Fair to Shareholders

October 28, 2025

From Halper Sadeh LLC

Via GlobeNewswire

Nucor To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

October 28, 2025

Via Benzinga

This Boot Barn Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗

October 28, 2025

Via Benzinga

Frequently Asked Questions

Is Atrium Therapeutics, Inc. - Common Stock publicly traded?

Yes, Atrium Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Atrium Therapeutics, Inc. - Common Stock trade on?

Atrium Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Atrium Therapeutics, Inc. - Common Stock?

The ticker symbol for Atrium Therapeutics, Inc. - Common Stock is RNA on the Nasdaq Stock Market

What is the current price of Atrium Therapeutics, Inc. - Common Stock?

The current price of Atrium Therapeutics, Inc. - Common Stock is 12.68

When was Atrium Therapeutics, Inc. - Common Stock last traded?

The last trade of Atrium Therapeutics, Inc. - Common Stock was at 06/01/26 04:00 PM ET

What is the market capitalization of Atrium Therapeutics, Inc. - Common Stock?

The market capitalization of Atrium Therapeutics, Inc. - Common Stock is 690.58M

How many shares of Atrium Therapeutics, Inc. - Common Stock are outstanding?

Atrium Therapeutics, Inc. - Common Stock has 691M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.